Clinical Trial Update: Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pidnarulex (CX-5461) in combination with cemiplimab (REGN2810) for refractory microsatellite-stable colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)
• Pidnarulex (CX-5461)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING